Clinical trials
Breast Cancer Screening clinical trials
Below are recruiting breast cancer screening clinical trials, each written for real people, not researchers. We’re tracking 619 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05035836RecruitingPhase 2
Test drug after early HER2-positive breast cancer surgery
This trial tests zanidatamab, a type of targeted antibody treatment, in people with early-stage HER2-positive breast cancer to see how well it works and how safe it is. Because it’s a single-arm pilot study, everyone in the study gets the drug, and you’ll likely be asked to undergo standard surgery if appropriate.
Houston, TexasAges 18 years+ - NCT05483283Recruiting
Latina women study to help access breast cancer care
This trial supports Latina women who have higher breast cancer risk and face added barriers (like cost, transportation, safety, or isolation) to get recommended breast screening and genetic risk information. It aims to help you understand your risk and access care when it’s due.
Chicago, IllinoisAges 30 years+ - NCT05501704RecruitingPhase 2
Testosterone-blocking therapy for male breast cancer
This Phase 2 study tests an oral treatment (called “ET”) to treat hormone-receptor–positive, HER2-negative invasive breast cancer in men. It may help shrink or control cancer without using standard cancer treatments first.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05740956RecruitingPhase 1
Drug study for cancers with HRR gene or HRD changes
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
Beijing, Beijing MunicipalityAges 18–75 - NCT05961111RecruitingEarly Phase 1
Oncolytic virus injection for advanced solid tumors
This early-phase trial tests an injection of a virus designed to attack cancer cells in people with advanced solid tumors. It is meant for situations where standard treatments have not worked (or you can’t/won’t take them) and when doctors can directly deliver the treatment to a tumor spot.
Linyi, ShandongAges 18–75 - NCT05981326Recruiting
Computer model to predict chemo response in early breast cancer
This study looks at how well a computer model can predict if breast cancer will completely respond to chemotherapy before surgery. It is for people with early-stage breast cancer who are about to start neoadjuvant chemotherapy.
AngersAges 18 years+ - NCT06081959RecruitingPhase 3
Study of SKB264 for advanced HR+/HER2- breast cancer
This trial tests a new drug called SKB264 for people with a common type of breast cancer (HR+/HER2-) that has spread or come back and has not responded to at least one round of chemotherapy. It aims to see if this treatment can help shrink tumors or slow the disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06143553RecruitingPhase 3
Paclitaxel micelles for metastatic breast cancer
This trial tests a new form of paclitaxel (a chemotherapy drug) for metastatic breast cancer that is HER2-negative. It may be an option if your cancer has returned or not improved after 2 to 4 previous treatments.
Nanjing, JiangsuAges 18 years+ - NCT06404697RecruitingPhase 2
Extra radiation to lymph nodes above collarbone for high-risk breast cancer
This trial tests giving a focused, higher dose of radiation to the lymph nodes above the collarbone after breast cancer treatment. It is for patients whose cancer did not fully disappear from those nodes after pre-surgery chemotherapy, to see if extra radiation can help prevent recurrence.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06508307RecruitingPhase 1
A study of an injected virus for advanced solid tumors
This trial tests a new treatment where a virus (GC001) is injected directly into a tumor. The virus is designed to attack cancer cells and may help people with advanced solid tumors that haven't responded to other treatments.
Zhengzhou, HenanAges 18–75 - NCT06545045Recruiting
Thinking and memory help after breast cancer treatment
This trial tests a cognitive rehabilitation program for breast cancer survivors who have ongoing problems with thinking, memory, or concentration after finishing treatment. The goal is to help improve daily mental function.
Columbia, MissouriAges 20–75 - NCT06633380Recruiting
Different physical activity strategies for breast cancer survivors
This study tests different ways to add physical activity into your daily routine to help manage side effects from breast cancer treatment. The goal is to see if simple, practical strategies can improve your health and well-being while you are on aromatase inhibitors.
Toronto, OntarioAges Any age - NCT07008976RecruitingPhase 3
Testing TQB2102 versus standard treatment for HER2-positive advanced breast cancer
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
Bengbu, AnhuiAges 18–75 - NCT07037199RecruitingPhase 2
A new drug combo for HR+ advanced breast cancer
This trial tests a sequence of three drugs: first trastuzumab rezetecan (a targeted therapy), then a CDK4/6 inhibitor plus hormone therapy. It's for people with a type of breast cancer called HR-positive, HER2-low or ultra-low that has spread or come back and has already progressed on a CDK4/6 inhibitor and hormone therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07162298RecruitingPhase 2
Dragon boat racing vs. home exercise for breast cancer patients
This study compares dragon boat racing with unsupervised home exercise to see which better improves physical function and quality of life in breast cancer patients. It may help you become more active and feel better during recovery.
HangzhouAges 18–75 - NCT07393425RecruitingPhase 2
Study of two targeted therapies before surgery for HER2+ breast cancer
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT02977468RecruitingPhase 1
Pembrolizumab for early triple-negative breast cancer tumor changes
This Phase 1 study tests pembrolizumab (an immune medicine) to see how it affects the tumor and its surroundings in triple-negative breast cancer. It’s mainly looking at safety and early signs of benefit, especially in a limited, early-stage breast tumor.
Atlanta, GeorgiaAges 21–80 - NCT07647016RecruitingPhase 2
New Drug Combination for Advanced Hormone-Receptor-Positive Breast Cancer
This study tests two drugs together—trastuzumab deruxtecan and ivonescimab—for advanced breast cancer that is hormone-receptor-positive but HER2-negative or HER2-low. These drugs work by targeting cancer cells in different ways and may help slow or shrink tumors in patients whose cancer has progressed after earlier treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07242352RecruitingPhase 3
Comparing elacestrant to standard hormone therapy for high-risk early breast cancer
This trial tests a new hormone therapy drug called elacestrant against standard hormone treatments for people with a specific type of early breast cancer (ER+/HER2-) that has a high chance of coming back. The goal is to see if elacestrant works better at keeping the cancer from returning.
Mannheim, Baden-WurttembergAges 18 years+ - NCT07112053RecruitingPhase 2
Vaccine with hormone therapy or chemo for advanced breast cancer
This trial tests a vaccine (STEMVAC) given with your standard hormone therapy or chemotherapy. It is for people with advanced hormone receptor-positive, HER2-negative breast cancer who are already on certain treatments. The goal is to see if adding the vaccine can help control the cancer better.
Seattle, WashingtonAges 18 years+ - NCT07078604RecruitingPhase 2
Vaccine with chemotherapy for advanced triple-negative breast cancer
This trial tests a cancer vaccine called STEMVAC combined with chemotherapy in people with a type of breast cancer that has spread and does not have certain markers. The goal is to see if adding the vaccine helps the chemotherapy work better.
Seattle, WashingtonAges 18 years+ - NCT05318469RecruitingPhase 1/Phase 2
Ivermectin with immunotherapy for metastatic triple-negative breast cancer
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Los Angeles, CaliforniaAges 18 years+ - NCT05491083RecruitingPhase 1/Phase 2
Pembrolizumab plus ADG106 for advanced triple-negative breast cancer
This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.
SingaporeAges 21–99
Hear when a new Breast Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer screening?
- Yes. Clin2 currently lists 619 recruiting breast cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.